NEW YORK - Hoth Therapeutics , Inc. (NASDAQ: NASDAQ:HOTH) has announced positive outcomes from pre-clinical research on HT-ALZ, a potential new treatment for Alzheimer's disease. The study, conducted by a team of researchers, focused on the Substance P/Neurokinin 1 Receptor pathway and its role in neuroinflammation and cognitive deficits associated with Alzheimer's.
The research team, which includes Carla Yuede, Kate M. Reardon, Ryan T. Harrigan, and John R. Cirrito, found that HT-ALZ could reduce soluble Aβ levels in the brain and improve cognitive functions in preclinical models.
Although the study's results on plaque deposition were inconclusive, the therapeutic showed a significant decrease in anxiety-like behavior and an enhancement in cognitive function, particularly in memory tasks and sensorimotor gating.
Despite the initial stage of research, Hoth Therapeutics is optimistic about the future of HT-ALZ, which aims to restore cognitive functions and improve the quality of life for individuals with Alzheimer's disease. The company is planning further research to better understand the effects of HT-ALZ on microglial activation and brain inflammation.
The full results of the study are expected to be published later this year, and a presentation of the data is scheduled to take place at an Alzheimer's Research Center group at Washington University in St. Louis. Hoth Therapeutics has emphasized its commitment to advancing the development of HT-ALZ and is focused on the potential benefits it may offer to patients with Alzheimer's.
This news is based on a press release statement and contains forward-looking statements subject to risks, uncertainties, and assumptions. Hoth Therapeutics continues to navigate the regulatory process, with the hope of bringing HT-ALZ closer to clinical application. The company's efforts are part of a broader mission to improve patient quality of life through innovative treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.